GLPwatch
Papers (10382)
Page 126 of 174, ranked by citation count.
- In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss.
- Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
- Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting.
- Managing diabetes in patients with diabetes of long duration.
- Bringing liraglutide to market: a CER case study.
- Liraglutide attenuates high glucose-induced endothelial cell senescence and dysfunction via SIRT1-mediated deacetylation of p53/p65.
- Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development.
- Liraglutide Treatment Reverses Unconventional Cellular Defects in Induced Pluripotent Stem Cell-Derived β-Cells Harboring a Partially Functional WFS1 Variant.
- Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
- Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status.
- Efficacy and Safety of Basal Insulin/GLP-1 Receptor Agonist Used in Combination for Type 2 Diabetes Management.
- Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.
- Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.
- Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models.
- Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.
- Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
- The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
- GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction.
- IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective.
- Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutide.
- Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.
- Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.
- Supramolecular prodrug of SN38 based on endogenous albumin and SN38 prodrug modified with semaglutide side chain to improve the tumor distribution.
- GLP-1RA partially alleviates obesity-induced reproductive dysfunction driven by the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway.
- Retinopathy risk factors in patients with type 2 diabetes on liraglutide.
- Dual Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Tirzepatide Use.
- Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization.
- Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes.
- Liraglutide treatment and acylcarnitine profiles in Egyptian obese insulin-resistant females.
- Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients.
- Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network.
- Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.
- Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.
- New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes.
- Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.
- Oral semaglutide: an OASIS from injectables.
- Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss.
- A software interface for in silico testing of type 2 diabetes treatments.
- Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.
- Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.
- GLP-1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review.
- Liraglutide modulates ALCAT1-Mediated cardiolipin remodeling to improve cardiac function in obese mice.
- Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.
- Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
- Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.
- Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study.
- FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue.
- [Effect of exendin-4 on lipid deposition in skeletal muscle of diet-induced obese mice and its underlying mechanism].
- Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report.
- Exploring beyond numeric weight loss: The metabolic effects of semaglutide.
- Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.
- Repeated Withdrawal of a GLPR Agonist Induces Hyperleptinemia and Deteriorates Metabolic Health in Obese Aging UM-HET3 Mice.
- Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
- Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
- Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment.
- Maturity-Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report.
- Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.
- Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.
- Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.
- Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report.